

Oral anticoagulants in patients with coronary artery disease. Anand, S. S. and S. Yusuf. *J Am Coll Cardiol* (2003).**41**(4 Suppl S): 62S-69S

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12644343

Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. Antman, E. M. *Am Heart J* (2003).**146**(4 Suppl): S18-22

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14564302

Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). Ashby, D. T., E. A. Aymong, et al. *Am J Cardiol* (2003).**92**(9): 1091-4

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14583362

Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. Ashby, D. T., G. Dangas, et al. *Am J Cardiol* (2003).**92**(3): 319-22

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12888144

Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Azar, R. R., S. Klayme, et al. *Am J Cardiol* (2003).**92**(2): 236-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12860235

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Barragan, P., J. L. Bouvier, et al. *Catheter Cardiovasc Interv* (2003).**59**(3): 295-302

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12822144

Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. Bauriedel, G., D. Skowasch, et al. *Am Heart J* (2003).**145**(2): 343-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12595854

Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Best, P. J., R. Lennon, et al. *Am Heart J* (2003).**146**(2): 345-50

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12891206

Safety of concomitant therapy with eptifibatid and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. Bhatt,

D. L., B. I. Lee, et al. J Am Coll Cardiol (2003).**41**(1): 20-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12570939

The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. Bijsterveld, N. R., A. H. Moons, et al. J Am Coll Cardiol (2003).**42**(3): 424-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12906966

Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Bonz, A. W., B. Lengenfelder, et al. Am Heart J (2003).**145**(4): 693-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12679767

Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry. Brener, S. J., S. G. Ellis, et al. Eur Heart J (2003).**24**(7): 630-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12657221

Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Budaj, A., D. Brieger, et al. Am Heart J (2003).**146**(6): 999-1006

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14660991

Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial.

Cannon, C. P. J Am Coll Cardiol (2003).**41**(4 Suppl S): 43S-48S

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12644340

Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial. Casserly, I. P., E. J. Topol, et al. Am J Cardiol (2003).**92**(2): 125-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12860211

Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET). Chan, A. W., D. J. Moliterno, et al. J Am Coll Cardiol (2003).**42**(7): 1188-95

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14522478

Bivalirudin provides increasing benefit with decreasing renal function: a

meta-analysis of randomized trials. Chew, D. P., D. L. Bhatt, et al. Am J Cardiol (2003).**92**(8): 919-23

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14556866

Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.

Cho, L., D. P. Chew, et al. Am J Cardiol (2003).**91**(6): 742-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12633814

The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.

Cohen, M., G. F. Gensini, et al. J Am Coll Cardiol (2003).**42**(8): 1348-56

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14563573

The role of low-molecular-weight heparin in the management of acute coronary syndromes. Cohen, M. J Am Coll Cardiol (2003).**41**(4 Suppl S): 55S-61S

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12644342

Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction.

Cutlip, D. E., M. J. Ricciardi, et al. Am J Cardiol (2003).**92**(8): 977-80

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14556878

Synergistic treatment of ST-segment elevation myocardial infarction with pharmacoinvasive recanalization. Dauerman, H. L. and B. E. Sobel. J Am Coll Cardiol (2003).**42**(4): 646-51

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12932595

Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention.

Denardo, S. J., K. E. Davis, et al. Am J Cardiol (2003).**91**(1): 1-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12505562

Effect of single dose of intravenous heparin on plasma levels of angiogenic growth factors. East, M. A., D. I. Landis, et al. Am J Cardiol (2003).**91**(10): 1234-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12745108

The evolving role of direct thrombin inhibitors in acute coronary syndromes.

Eikelboom, J., H. White, et al. J Am Coll Cardiol (2003).**41**(4 Suppl S): 70S-78S

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12745108

[tation&list_uids=12644344](#)

Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction. Eisenberg, M. J. and S. Jamal. J Am Coll Cardiol (2003).**42**(1): 1-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12849651

Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson, J. J., E. M. Antman, et al. Am Heart J (2003).**146**(4): 628-34

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14564315

Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. Freeman, R. V., R. H. Mehta, et al. J Am Coll Cardiol (2003).**41**(5): 718-24

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12628712

The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable? Gerschutz, G. P. and D. L. Bhatt. Am Heart J (2003).**145**(4): 595-601

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12679754

Coronary angioplasty enhances platelet reactivity through von Willebrand factor release. Gorog, D. A., H. Douglas, et al. Heart (2003).**89**(3): 329-30

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12591846

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. Gum, P. A., K. Kottke-Marchant, et al. J Am Coll Cardiol (2003).**41**(6): 961-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12651041

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Gurbel, P. A., K. P. Bliden, et al. Circulation (2003).**107**(23): 2908-13

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12796140

Platelet activation after stenting with heparin-coated versus noncoated stents. Gurbel, P. A. and K. P. Bliden. Am Heart J (2003).**146**(4): E10

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14564333

Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Gurbel, P. A., C. C. Cummings, et al.

Am Heart J (2003).**145**(2): 239-47

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12595840

Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. Heitzer, T., I. Ollmann, et al. Circulation (2003).**108**(5): 536-41

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12874186

Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry). Horwitz, P. A., J. A. Berlin, et al. Am J Cardiol (2003).**91**(7): 803-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12667564

Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Huynh, T., P. Theroux, et al. Am Heart J (2003).**146**(4): 668-73

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14564321

Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. Januzzi, J. L., C. P. Cannon, et al. Am Heart J (2003).**146**(5): 764-74

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14597924

Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. Karvouni, E., D. G. Katriasis, et al. J Am Coll Cardiol (2003).**41**(1): 26-32

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12570940

Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Kong, D. F., V. Hasselblad, et al. Am J Cardiol (2003).**92**(6): 651-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12972100

Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Lee, D. P., N. A. Herity, et al. Circulation (2003).**107**(11): 1497-501

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12654606

Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy

for the future. Leon, M. B. and A. Bakhai. Am Heart J (2003).**146**(4 Suppl): S13-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14564301

Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where? Lincoff, A. M. Am Heart J (2003).**146**(4 Suppl): S23-30

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14564303

The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. Marmur, J. D., S. X. Anand, et al. J Am Coll Cardiol (2003).**41**(3): 394-402

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12575965

Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting. Massberg, S., I. Mueller, et al. Am Heart J (2003).**146**(5): E19

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14597948

Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting. Massberg, S., I. Mueller, et al. Am Heart J (2003).**146**(5): E19

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14597948

Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study. Mehran, R., E. D. Aymong, et al. Circulation (2003).**108**(9): 1078-83

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12925457

Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. Mehta, S. R. and S. Yusuf. J Am Coll Cardiol (2003).**41**(4 Suppl S): 79S-88S

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12644345

Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Michalis, L. K., C. S. Katsouras, et al. Am Heart J (2003).**146**(2): 304-10

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12891200

A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. Moliterno, D. J., J. B. Hermiller, et al. J Am Coll Cardiol (2003).**42**(6): 1132-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=13678943

Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET.

Moliterno, D. J. and A. W. Chan. *J Am Coll Cardiol* (2003).**41**(4 Suppl S): 49S-54S

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12644341

Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE). Montalescot, G., F. Van De Werf, et al. *Catheter Cardiovasc Interv* (2003).**60**(3): 360-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14571488

A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. Mueller, C., H. Roskamm, et al. *J Am Coll Cardiol* (2003).**41**(6): 969-73

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12651043

Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Nannizzi-Alaimo, L., V. L. Alves, et al. *Circulation* (2003).**107**(8): 1123-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12615789

Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial. Ottervanger, J. P., P. Armstrong, et al. *Circulation* (2003).**107**(3): 437-42

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12551868

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.

Peters, R. J., S. R. Mehta, et al. *Circulation* (2003).**108**(14): 1682-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14504182

Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. Peterson, E. D., C. V. Pollack, Jr., et al. *J Am Coll Cardiol* (2003).**42**(1): 45-53

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12849658

Angiographic variables predict increased risk for adverse ischemic events

after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. Ross, M. J., H. C. Herrmann, et al. J Am Coll Cardiol (2003).**42**(6): 981-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=13678916

Percutaneous coronary interventions in octogenarians. glycoprotein IIb/IIIa receptor inhibitors' safety profile. Sadeghi, H. M., C. L. Grines, et al. J Am Coll Cardiol (2003).**42**(3): 428-32

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12906967

Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban.

Schneider, D. J., H. C. Herrmann, et al. Am J Cardiol (2003).**91**(3): 334-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12565092

Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Soffer, D., I. Moussa, et al.

Catheter Cardiovasc Interv (2003).**59**(1): 21-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12720236

Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis.

Sperling, R. T., D. S. Pinto, et al. Catheter Cardiovasc Interv (2003).**59**(4): 459-62

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12891606

Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.

Spinler, S. A., S. M. Inverso, et al. Am Heart J (2003).**146**(1): 33-41

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12851605

What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? Steinhubl, S. and P. Berger.

Am Heart J (2003).**145**(6): 971-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12796751

Relation of local platelet glycoprotein IIb/IIIa independent activation during coronary angioplasty in acute myocardial infarction to recovery of left ventricular function.

Taylor, A. J., A. Bobik, et al. Am J Cardiol (2003).**92**(4): 446-50

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12914877

Meta-analysis of randomized trials comparing enoxaparin versus

unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. Theroux, P. and R. C. Welsh. Am J Cardiol (2003).**91**(7): 860-4

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12667572

Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. Tolleson, T. R., J. C. O'Shea, et al. J Am Coll Cardiol (2003).**41**(3): 386-93

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12575964

A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.

Vakili, B. A., R. C. Kaplan, et al. Am J Cardiol (2003).**91**(8): 946-50

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12686333

Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. Watanabe, K., S. Ikeda, et al. Am J Cardiol (2003).**92**(1): 21-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12842239

Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.

Wienbergen, H., A. K. Gitt, et al. Am J Cardiol (2003).**92**(3): 285-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12888133

Clinical impact of abciximab on long-term outcome after complex coronary angioplasty. Wijpkema, J. S., G. A. Jessurun, et al. Catheter Cardiovasc Interv (2003).**60**(3): 339-43

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14571484

Clinical impact of abciximab on long-term outcome after complex coronary angioplasty. Wijpkema, J. S., G. A. Jessurun, et al. Catheter Cardiovasc Interv (2003).**60**(3): 339-43

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14571484

Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Wohrle, J., O. C. Grebe, et al. Circulation (2003).**107**(14): 1840-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12682003

Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention. Wolfram, R., L. Leborgne, et al. Am J Cardiol (2003).**92**(9): 1080-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14583359

Early and late effects of clopidogrel in patients with acute coronary syndromes. Yusuf, S., S. R. Mehta, et al. *Circulation* (2003).**107**(7): 966-72
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12600908

Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke. Zhang, L., Z. G. Zhang, et al. *Circulation* (2003).**107**(22): 2837-43
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12756151

Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Kakkar, A. K., A. Moustapha, et al. *Catheter Cardiovasc Interv* (2004).**61**(1): 31-4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14696156

A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel. Kastrati, A., J. Mehilli, et al. *N Engl J Med* (2004).**350**(3): 232-238 <http://content.nejm.org/cgi/content/abstract/350/3/232>

Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Martin, J. L., E. T. Fry, et al. *Catheter Cardiovasc Interv* (2004).**61**(2): 163-70
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14755805

GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Welt, F. G., S. D. Rogers, et al. *Catheter Cardiovasc Interv* (2004).**61**(2): 185-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14755809